Is Innova Captab overvalued or undervalued?

As of 4 November 2025, the valuation grade for Innova Captab has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 36.20, an EV to EBITDA ratio of 25.34, and a ROE of 13.37%.
In comparison to its peers, Innova Captab's PE ratio is slightly higher than Sun Pharma's 35.41, which is considered expensive, while it remains significantly lower than Divi's Lab's very expensive PE of 78.59. Other peers like Cipla and Dr. Reddy's Labs are rated attractive with PE ratios of 22.35 and 17.36, respectively. Despite recent stock performance lagging behind the Sensex over the year, with a YTD return of -25.63% compared to the Sensex's 6.81%, the current valuation suggests that Innova Captab is fairly positioned in the market.